vs

Side-by-side financial comparison of Claritev Corp (CTEV) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

Claritev Corp is the larger business by last-quarter revenue ($246.6M vs $197.9M, roughly 1.2× REPLIGEN CORP). REPLIGEN CORP runs the higher net margin — 6.7% vs -32.7%, a 39.4% gap on every dollar of revenue. On growth, REPLIGEN CORP posted the faster year-over-year revenue change (13.6% vs 6.2%). Claritev Corp produced more free cash flow last quarter ($36.4M vs $17.6M). Over the past eight quarters, REPLIGEN CORP's revenue compounded faster (14.4% CAGR vs 2.5%).

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

CTEV vs RGEN — Head-to-Head

Bigger by revenue
CTEV
CTEV
1.2× larger
CTEV
$246.6M
$197.9M
RGEN
Growing faster (revenue YoY)
RGEN
RGEN
+7.4% gap
RGEN
13.6%
6.2%
CTEV
Higher net margin
RGEN
RGEN
39.4% more per $
RGEN
6.7%
-32.7%
CTEV
More free cash flow
CTEV
CTEV
$18.8M more FCF
CTEV
$36.4M
$17.6M
RGEN
Faster 2-yr revenue CAGR
RGEN
RGEN
Annualised
RGEN
14.4%
2.5%
CTEV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTEV
CTEV
RGEN
RGEN
Revenue
$246.6M
$197.9M
Net Profit
$-80.6M
$13.3M
Gross Margin
52.5%
Operating Margin
-3.1%
9.0%
Net Margin
-32.7%
6.7%
Revenue YoY
6.2%
13.6%
Net Profit YoY
41.6%
143.9%
EPS (diluted)
$-4.88
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTEV
CTEV
RGEN
RGEN
Q4 25
$246.6M
$197.9M
Q3 25
$246.0M
$188.8M
Q2 25
$241.6M
$182.4M
Q1 25
$231.3M
$169.2M
Q4 24
$232.1M
$174.1M
Q3 24
$230.5M
$154.9M
Q2 24
$233.5M
$154.1M
Q1 24
$234.5M
$151.3M
Net Profit
CTEV
CTEV
RGEN
RGEN
Q4 25
$-80.6M
$13.3M
Q3 25
$-69.8M
$14.9M
Q2 25
$-62.6M
$14.9M
Q1 25
$-71.3M
$5.8M
Q4 24
$-138.0M
$-30.3M
Q3 24
$-391.4M
$-654.0K
Q2 24
$-576.7M
$3.3M
Q1 24
$-539.7M
$2.1M
Gross Margin
CTEV
CTEV
RGEN
RGEN
Q4 25
52.5%
Q3 25
53.2%
Q2 25
50.0%
Q1 25
53.6%
Q4 24
26.1%
Q3 24
50.0%
Q2 24
49.8%
Q1 24
49.5%
Operating Margin
CTEV
CTEV
RGEN
RGEN
Q4 25
-3.1%
9.0%
Q3 25
4.1%
8.9%
Q2 25
6.9%
7.6%
Q1 25
4.2%
3.9%
Q4 24
-17.8%
-17.7%
Q3 24
-146.7%
-5.1%
Q2 24
-224.4%
1.0%
Q1 24
-207.4%
1.3%
Net Margin
CTEV
CTEV
RGEN
RGEN
Q4 25
-32.7%
6.7%
Q3 25
-28.4%
7.9%
Q2 25
-25.9%
8.2%
Q1 25
-30.8%
3.4%
Q4 24
-59.4%
-17.4%
Q3 24
-169.8%
-0.4%
Q2 24
-247.0%
2.2%
Q1 24
-230.1%
1.4%
EPS (diluted)
CTEV
CTEV
RGEN
RGEN
Q4 25
$-4.88
$0.24
Q3 25
$-4.23
$0.26
Q2 25
$-3.81
$0.26
Q1 25
$-4.38
$0.10
Q4 24
$-8.49
$-0.55
Q3 24
$-24.25
$-0.01
Q2 24
$-35.78
$0.06
Q1 24
$-33.40
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTEV
CTEV
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$16.8M
$767.6M
Total DebtLower is stronger
$4.6B
$542.2M
Stockholders' EquityBook value
$-173.9M
$2.1B
Total Assets
$4.9B
$2.9B
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTEV
CTEV
RGEN
RGEN
Q4 25
$16.8M
$767.6M
Q3 25
$39.2M
$748.7M
Q2 25
$56.4M
$708.9M
Q1 25
$23.1M
$697.2M
Q4 24
$16.8M
$757.4M
Q3 24
$86.6M
$784.0M
Q2 24
$48.8M
$809.1M
Q1 24
$58.7M
$780.6M
Total Debt
CTEV
CTEV
RGEN
RGEN
Q4 25
$4.6B
$542.2M
Q3 25
$4.5B
$537.9M
Q2 25
$4.5B
Q1 25
$4.5B
Q4 24
$4.5B
$525.6M
Q3 24
$4.5B
Q2 24
$4.5B
Q1 24
$4.5B
Stockholders' Equity
CTEV
CTEV
RGEN
RGEN
Q4 25
$-173.9M
$2.1B
Q3 25
$-101.8M
$2.1B
Q2 25
$-39.9M
$2.1B
Q1 25
$14.8M
$2.0B
Q4 24
$84.0M
$2.0B
Q3 24
$207.6M
$2.0B
Q2 24
$603.4M
$2.0B
Q1 24
$1.2B
$2.0B
Total Assets
CTEV
CTEV
RGEN
RGEN
Q4 25
$4.9B
$2.9B
Q3 25
$5.0B
$2.9B
Q2 25
$5.1B
$2.9B
Q1 25
$5.1B
$2.9B
Q4 24
$5.2B
$2.8B
Q3 24
$5.3B
$2.8B
Q2 24
$5.7B
$2.9B
Q1 24
$6.4B
$2.8B
Debt / Equity
CTEV
CTEV
RGEN
RGEN
Q4 25
0.26×
Q3 25
0.26×
Q2 25
Q1 25
304.87×
Q4 24
53.67×
0.27×
Q3 24
21.73×
Q2 24
7.48×
Q1 24
3.85×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTEV
CTEV
RGEN
RGEN
Operating Cash FlowLast quarter
$66.3M
$25.7M
Free Cash FlowOCF − Capex
$36.4M
$17.6M
FCF MarginFCF / Revenue
14.8%
8.9%
Capex IntensityCapex / Revenue
12.1%
4.1%
Cash ConversionOCF / Net Profit
1.93×
TTM Free Cash FlowTrailing 4 quarters
$-12.3M
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTEV
CTEV
RGEN
RGEN
Q4 25
$66.3M
$25.7M
Q3 25
$19.9M
$48.1M
Q2 25
$61.2M
$28.6M
Q1 25
$-30.1M
$15.0M
Q4 24
$-33.4M
$39.2M
Q3 24
$72.8M
$49.3M
Q2 24
$18.5M
$42.2M
Q1 24
$49.7M
$44.7M
Free Cash Flow
CTEV
CTEV
RGEN
RGEN
Q4 25
$36.4M
$17.6M
Q3 25
$-16.3M
$43.4M
Q2 25
$36.6M
$21.5M
Q1 25
$-68.9M
$11.4M
Q4 24
$-63.8M
$33.6M
Q3 24
$41.1M
$42.3M
Q2 24
$-7.0M
$37.4M
Q1 24
$19.2M
$36.4M
FCF Margin
CTEV
CTEV
RGEN
RGEN
Q4 25
14.8%
8.9%
Q3 25
-6.6%
23.0%
Q2 25
15.2%
11.8%
Q1 25
-29.8%
6.8%
Q4 24
-27.5%
19.3%
Q3 24
17.8%
27.3%
Q2 24
-3.0%
24.3%
Q1 24
8.2%
24.0%
Capex Intensity
CTEV
CTEV
RGEN
RGEN
Q4 25
12.1%
4.1%
Q3 25
14.7%
2.5%
Q2 25
10.2%
3.9%
Q1 25
16.8%
2.1%
Q4 24
13.1%
3.2%
Q3 24
13.8%
4.5%
Q2 24
10.9%
3.1%
Q1 24
13.0%
5.5%
Cash Conversion
CTEV
CTEV
RGEN
RGEN
Q4 25
1.93×
Q3 25
3.23×
Q2 25
1.92×
Q1 25
2.57×
Q4 24
Q3 24
Q2 24
12.70×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons